Kyverna Therapeutics (KYTX) Total Current Liabilities (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Total Current Liabilities data on file, last reported at $29.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 10.87% year-over-year to $29.7 million; the trailing twelve-month figure through Mar 2026 stood at $29.7 million (down 10.87% YoY), and the FY2025 full-year result was $36.5 million, up 8.09% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $29.7 million, down from $36.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $39.8 million in Q2 2025 and bottomed at $19.9 million in Q4 2023.
• The 4-year median for Total Current Liabilities is $32.1 million (2024), against an average of $30.3 million.
• The widest annual swing landed in 2024, when Total Current Liabilities soared 69.98%; it then fell 10.87% in 2026.
• A 4-year view of Total Current Liabilities shows it stood at $19.9 million in 2023, then jumped by 69.98% to $33.8 million in 2024, then rose by 8.09% to $36.5 million in 2025, then decreased by 18.67% to $29.7 million in 2026.
• The last three Total Current Liabilities figures came in at $29.7 million (Q1 2026), $36.5 million (Q4 2025), and $33.9 million (Q3 2025), per Business Quant data.

Peer Comparison